Mobilise App Lab provides cloud-based enterprise software and subscription services that help organizations automate administrative tasks, manage physical assets, and digitize human resource and supply chain workflows.
The company exhibits high switching costs through its integrated ERP and asset management platforms which become embedded in client operations, evidenced by a very high average ROCE of 69% and healthy net margins.
Earnings are primarily reinvested into intangible software development and R&D, with a recent focus on using IPO proceeds for talent acquisition and infrastructure rather than dividends.
The business collapsed because the massive divergence between revenue growth and earnings—already visible in the 96% EPS contraction—proved to be a permanent feature of a low-barrier software service model rather than a temporary scaling cost. Despite high historical ROCE, the company failed to translate its ERP platforms into a defensible ecosystem, as the 'integrated' software was easily displaced by larger, better-capitalized competitors. The revolving door of CFOs and Company Secretaries eventually signaled deeper internal control failures, and the related-party loans from the Managing Director evolved from a liquidity bridge into a mechanism for capital misallocation, leaving shareholders with a hollowed-out shell of a once-promising tech firm.
RichFakir rates Mobilise App Lab Ltd's business quality as mediocre — 66/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Mobilise App Lab Ltd is trading about 25% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Mobilise App Lab Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Mobilise App Lab Ltd's fair value is about ₹77 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →